PMID- 22703610
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121017
LR  - 20211021
IS  - 2045-9912 (Electronic)
IS  - 2045-9912 (Linking)
VI  - 2
IP  - 1
DP  - 2012 Jun 15
TI  - Hyperbaric oxygen treatment in autism spectrum disorders.
PG  - 16
LID - 10.1186/2045-9912-2-16 [doi]
AB  - Traditionally, hyperbaric oxygen treatment (HBOT) is indicated in several 
      clinical disorders include decompression sickness, healing of problem wounds and 
      arterial gas embolism. However, some investigators have used HBOT to treat 
      individuals with autism spectrum disorders (ASD). A number of individuals with 
      ASD possess certain physiological abnormalities that HBOT might ameliorate, 
      including cerebral hypoperfusion, inflammation, mitochondrial dysfunction and 
      oxidative stress. Studies of children with ASD have found positive changes in 
      physiology and/or behavior from HBOT. For example, several studies have reported 
      that HBOT improved cerebral perfusion, decreased markers of inflammation and did 
      not worsen oxidative stress markers in children with ASD. Most studies of HBOT in 
      children with ASD examined changes in behaviors and reported improvements in 
      several behavioral domains although many of these studies were not controlled. 
      Although the two trials employing a control group reported conflicting results, a 
      recent systematic review noted several important distinctions between these 
      trials. In the reviewed studies, HBOT had minimal adverse effects and was well 
      tolerated. Studies which used a higher frequency of HBOT sessions (e.g., 10 
      sessions per week as opposed to 5 sessions per week) generally reported more 
      significant improvements. Many of the studies had limitations which may have 
      contributed to inconsistent findings across studies, including the use of many 
      different standardized and non-standardized instruments, making it difficult to 
      directly compare the results of studies or to know if there are specific areas of 
      behavior in which HBOT is most effective. The variability in results between 
      studies could also have been due to certain subgroups of children with ASD 
      responding differently to HBOT. Most of the reviewed studies relied on changes in 
      behavioral measurements, which may lag behind physiological changes. Additional 
      studies enrolling children with ASD who have certain physiological abnormalities 
      (such as inflammation, cerebral hypoperfusion, and mitochondrial dysfunction) and 
      which measure changes in these physiological parameters would be helpful in 
      further defining the effects of HBOT in ASD.
FAU - Rossignol, Daniel A
AU  - Rossignol DA
AD  - Rossignol Medical Center, 3800 West Eau Gallie Blvd,, Melbourne, FL, 32934, USA. 
      rossignolmd@gmail.com.
FAU - Bradstreet, James J
AU  - Bradstreet JJ
FAU - Van Dyke, Kyle
AU  - Van Dyke K
FAU - Schneider, Cindy
AU  - Schneider C
FAU - Freedenfeld, Stuart H
AU  - Freedenfeld SH
FAU - O'Hara, Nancy
AU  - O'Hara N
FAU - Cave, Stephanie
AU  - Cave S
FAU - Buckley, Julie A
AU  - Buckley JA
FAU - Mumper, Elizabeth A
AU  - Mumper EA
FAU - Frye, Richard E
AU  - Frye RE
LA  - eng
GR  - TL1 RR024147/RR/NCRR NIH HHS/United States
GR  - UL1 RR024148/RR/NCRR NIH HHS/United States
PT  - Journal Article
DEP - 20120615
PL  - Australia
TA  - Med Gas Res
JT  - Medical gas research
JID - 101564536
PMC - PMC3472266
EDAT- 2012/06/19 06:00
MHDA- 2012/06/19 06:01
PMCR- 2012/06/15
CRDT- 2012/06/19 06:00
PHST- 2012/03/29 00:00 [received]
PHST- 2012/05/19 00:00 [accepted]
PHST- 2012/06/19 06:00 [entrez]
PHST- 2012/06/19 06:00 [pubmed]
PHST- 2012/06/19 06:01 [medline]
PHST- 2012/06/15 00:00 [pmc-release]
AID - 2045-9912-2-16 [pii]
AID - 10.1186/2045-9912-2-16 [doi]
PST - epublish
SO  - Med Gas Res. 2012 Jun 15;2(1):16. doi: 10.1186/2045-9912-2-16.